196 related articles for article (PubMed ID: 29940575)
1. Knockdown of MiR-20a Enhances Sensitivity of Colorectal Cancer Cells to Cisplatin by Increasing ASK1 Expression.
Zhang L; He L; Zhang H; Chen Y
Cell Physiol Biochem; 2018; 47(4):1432-1441. PubMed ID: 29940575
[TBL] [Abstract][Full Text] [Related]
2. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Chai H; Liu M; Tian R; Li X; Tang H
Acta Biochim Biophys Sin (Shanghai); 2011 Mar; 43(3):217-25. PubMed ID: 21242194
[TBL] [Abstract][Full Text] [Related]
3. miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer.
Huang G; Chen X; Cai Y; Wang X; Xing C
Oncol Rep; 2017 Jan; 37(1):571-578. PubMed ID: 28004114
[TBL] [Abstract][Full Text] [Related]
4. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
5. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
6. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
7. miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB.
Du Y; Zhu M; Zhou X; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Tumour Biol; 2016 Jan; 37(1):1261-9. PubMed ID: 26286834
[TBL] [Abstract][Full Text] [Related]
8. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
Lv T; Song K; Zhang L; Li W; Chen Y; Diao Y; Yao Q; Liu P
Biochem Cell Biol; 2018 Oct; 96(5):663-671. PubMed ID: 29561664
[TBL] [Abstract][Full Text] [Related]
9. MicroR-545 mediates colorectal cancer cells proliferation through up-regulating epidermal growth factor receptor expression in HOTAIR long non-coding RNA dependent.
Huang X; Lu S
Mol Cell Biochem; 2017 Jul; 431(1-2):45-54. PubMed ID: 28364379
[TBL] [Abstract][Full Text] [Related]
10. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
11. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.
Zeng T; Luo L; Huang Y; Ye X; Lin J
Biomed Res Int; 2021; 2021():6665918. PubMed ID: 33748276
[TBL] [Abstract][Full Text] [Related]
14. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
15. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
16. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
Shi L; Xi J; Xu X; Peng B; Zhang B
Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
[TBL] [Abstract][Full Text] [Related]
17. miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1.
Wu G; Zhou W; Pan X; Sun Y; Xu H; Shi P; Li J; Gao L; Tian X
Cell Physiol Biochem; 2018; 47(5):2077-2087. PubMed ID: 29975932
[TBL] [Abstract][Full Text] [Related]
18. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
19. miR-106a Increases Granulosa Cell Viability and Is Downregulated in Women With Diminished Ovarian Reserve.
Hong L; Peng S; Li Y; Fang Y; Wang Q; Klausen C; Yin C; Wang S; Leung PCK; Yang X
J Clin Endocrinol Metab; 2018 Jun; 103(6):2157-2166. PubMed ID: 29590425
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Mir-135b Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Apoptosis Through Increase of FOXO1.
Qin Y; Li L; Wang F; Zhou X; Liu Y; Yin Y; Qi X
Cell Physiol Biochem; 2018; 48(4):1628-1637. PubMed ID: 30071508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
